ClinicalTrials.gg
RecruitingNCT07300267Updated Oct 2, 2026

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

A Phase 1 interventional study of V118C (Stage 1) and V118C (Stage 2) in Pneumococcal Infection, sponsored by Merck Sharp & Dohme LLC. Recruiting at 15 sites in United States. Open to participants aged 2 Months to 15 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Prevention

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 2, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
2 Months to 15 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Planned enrollment
18th of 19
210 · median 668
Started
2026
with 1 other
Phase 1
3 of 19
1 open now
Registered
18th of 19
by date
Lead sponsor
1 of 19
Merck Sharp & Dohme LLC

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 18th largest by planned enrollment, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 18th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 2 Months to 15 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

Researchers are looking for new vaccines to prevent pneumococcal disease, which is any infection in the lungs or other parts of the body that is caused by a type of bacteria called Streptococcus pneumoniae. V118C is a new vaccine designed to help prevent disease from Streptococcus pneumoniae bacteria.

This study will look at V118C in toddlers and infants. The goal of the study is to learn how safe V118C is for children and how well they tolerate it.

Read the detailed description

Stage 1 of the study will be conducted in toddlers enrolled at 12 through 15 months of age who previously completed a primary 3-dose infant series with a licensed pneumococcal conjugate vaccine (PCV). Stage 2 will be conducted in infants enrolled at approximately 2 months of age, who will receive the 3+1 schedule (3 infant doses followed by a toddler dose).

03

Conditions studied

  • Pneumococcal Infection
04

Who can participate

Ages eligible
2 Months to 15 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

Stage 1:

  • Is previously vaccinated with 3 routine infant doses of Pneumococcal 20-valent conjugate vaccine (PCV20)
  • Is 12 through 15 months of age

Stage 2:

- Is approximately 2 months of age

Both Stages:

  • Was born at full term (gestational age greater than or equal to 37 weeks)

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

Stage 1:

- Has received a PCV dose at 10 months of age and older

Stage 2:

  • Has received prior administration of any pneumococcal vaccine

Both stages:

  • Has a history of invasive pneumococcal disease (IPD)
  • Has a known to any component of V118C or PCV20 including diphtheria toxoid
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (estimated)

Study arms

  • Experimental
    V118C (Stage 1)

    Participants will receive a single 0.5 mL intramuscular (IM) injection of V118C administered at 12 to 15 months of age.

    Biological: V118C (Stage 1)

  • Experimental
    V118C (Stage 2)

    Participants will receive a single 0.5 mL IM injection of V118C administered at 2,4,6, and 12 months of age.

    Biological: V118C (Stage 2)

  • Active comparator
    PCV20 (Stage 1)

    Participants will receive a single 0.5 mL IM injection of PCV20 administered at 12 to 15 months of age.

    Biological: PCV20 (Stage 1)

  • Active comparator
    PCV20 (Stage 2)

    Participants will receive a single 0.5 mL IM injection of PCV20 administered at 2,4,6, and 12 months of age.

    Biological: PCV20 (Stage 2)

Interventions

  • BiologicalV118C (Stage 1)

    IM administration of V118C

  • BiologicalV118C (Stage 2)

    IM administration of V118C

  • BiologicalPCV20 (Stage 1)

    IM administration of PCV20

  • BiologicalPCV20 (Stage 2)

    IM administration of PCV20

06

What researchers measure

Primary outcomes

  1. Stage 1: Percentage of Participants With Immediate Adverse Events (AEs) Following Vaccination

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with immediate AEs following vaccination will be reported.

    Time frame: Up to approximately 30 minutes postvaccination

  2. Stage 1: Percentage of Participants With Solicited Injection-Site Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A solicited AE is a predefined event that participants legally acceptable representative (LAR) are specifically asked about and record on their electronic vaccine report card (eVRC). Solicited injection-site AEs include redness, swelling, pain or tenderness and hard lump. Percentage of participants with solicited injection-site AEs will be reported.

    Time frame: Up to approximately 7 days postvaccination

  3. Stage 1: Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A solicited AE is a predefined event that participants LAR are specifically asked about and record on their eVRC. Solicited systemic AEs include irritability, drowsiness, appetite lost, hives or welts, and fever. Percentage of participants with solicited systemic AEs will be reported.

    Time frame: Up to approximately 7 days postvaccination

  4. Stage 1: Percentage of Participants With Unsolicited Systemic or Injection-Site AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE is an event that is not solicited using a eVRC and that is communicated by a participant. Percentage of participants with unsolicited Systemic or Injection-Site AEs will be reported.

    Time frame: Up to approximately 28 days postvaccination

  5. Stage 1: Percentage of Participants With Serious Adverse Events (SAEs)

    A serious adverse event (SAE) is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Percentage of participants with one or more SAEs will be reported.

    Time frame: Up to approximately 12 months postvaccination

  6. Stage 1: Percentage of Participants With Medically Attended AEs (MAAEs)

    A MAAE is defined as an adverse event in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Percentage of participants with MAAEs will be reported.

    Time frame: Up to approximately 12 months postvaccination

  7. Stage 2: Percentage of Participants With Immediate AEs Following Vaccination

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Percentage of participants with immediate AEs following vaccination will be reported.

    Time frame: Up to approximately 30 minutes after each vaccination

  8. Stage 2: Percentage of Participants With Solicited Injection-Site AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A solicited AE is a predefined event that participants LAR are specifically asked about and record on their eVRC. Solicited injection-site AEs include redness, swelling, pain or tenderness and hard lump. Percentage of participants with solicited injection-site AEs will be reported.

    Time frame: Up to approximately 7 days after each vaccination

  9. Stage 2: Percentage of Participants With Solicited Systemic AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A solicited AE is a predefined event that participants LAR are specifically asked about and record on their eVRC. Solicited systemic AEs include irritability, drowsiness, appetite lost, hives or welts, and fever. Percentage of participants with solicited systemic AEs will be recorded.

    Time frame: Up to approximately 7 days after each vaccination

  10. Stage 2: Percentage of Participants With Unsolicited Systemic or Injection-Site AEs

    An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An unsolicited AE is an event that is not solicited using a eVRC and that is communicated by a participant. Percentage of participants with unsolicited Systemic or Injection-Site AEs will be reported.

    Time frame: Up to approximately 28 days after each vaccination

  11. Stage 2: Percentage of Participants With SAEs

    A SAE is an AE that is life-threatening, requires or prolongs an existing hospitalization, results in persistent or significant disability or incapacity, is a congenital anomaly or birth defect, or is another important medical event deemed such by medical or scientific judgment. Percentage of participants with one or more SAEs will be reported.

    Time frame: Up to approximately 12 months postdose 4

  12. Stage 2: Percentage of Participants With MAAEs

    A MAAE is defined as an adverse event in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Percentage of participants with MAAEs will be reported.

    Time frame: Up to approximately 12 months postdose 4

Secondary outcomes

  1. Stage 1: Geometric Mean Concentrations (GMCs) of Serotype-Specific Immunoglobulin G (IgG)

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. GMCs of Serotype-specific IgG at 30 days postvaccination with V118C and PCV20 will be reported.

    Time frame: Up to approximately 30 days post vaccination

  2. Stage 1: Ratio of GMCs of Serotype-Specific IgG of V118C to PCV20 [V118C/PCV20]

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. Ratio of GMCs of serotype-specific IgG of V118C to PCV20 will be reported.

    Time frame: Approximately Day 30 postvaccination

  3. Stage 1: Geometric Mean Fold Rises (GMFRs) of Serotype-Specific Immunoglobulin G (IgG)

    Geometric mean fold rise (GMFR) is defined as the geometric mean of the ratio of concentration at Day 30 after vaccination divided by concentration at baseline. GMFRs of serotype-specific IgG from baseline (Day 1) to Day 30 with V118C and PCV20 for IgG responses will be reported.

    Time frame: Day 1 (Baseline) and approximately Day 30 postvaccination

  4. Stage 1: Percentage of Participants With a ≥ 4-fold Rise for Serotype Specific IgG Concentrations

    The percentage of participants with ≥4-fold rise from baseline (Day 1) to Day 30 with V118C and PCV20 for IgG responses will be reported.

    Time frame: Day 1 (Baseline) and approximately Day 30 postvaccination

  5. Stage 2: Percentage of Participants With IgG ≥0.35 μg/mL (Response Rates) for Serotype Specific IgG Concentrations at 30 Days Postdose 3

    Percentage of participants with IgG ≥0.35 μg/mL (response rates) for each serotype at 30 days postdose 3 (PD3) with V118C and PCV20 will be reported will be reported.

    Time frame: Up to approximately 30 days postdose 3

  6. Stage 2: Percentage of Participants With IgG ≥0.35 μg/mL (Response Rates) for Serotype Specific IgG Concentrations at 30 Days Predose 4

    Percentage of participants with IgG ≥0.35 μg/mL (response rates) for each serotype at predose 4 (PD4) with V118C and PCV20 will be reported.

    Time frame: Up to approximately 6 months post dose 3

  7. Stage 2: Percentage of Participants With IgG ≥0.35 μg/mL (Response Rates) for Serotype Specific IgG Concentrations at 30 Days Postdose 4

    Percentage of participants with IgG ≥0.35 μg/mL (response rates) for each serotype at 30 days postdose 4 with V118C and PCV20 will be reported.

    Time frame: Up to approximately 30 days postdose 4

  8. Stage 2: Difference in the Response Rates [V118C minus PCV20] for Each Serotype at 30 Days Postdose 3

    Difference in the response rates \[V118C minus PCV20\] for each serotype at 30 days postdose 3 with V118C and PCV20 will be reported.

    Time frame: Up to approximately 30 days postdose 3

  9. Stage 2: Difference in the Response Rates [V118C Minus PCV20] for Each Serotype at 30 Days Postdose 4

    Difference in the response rates \[V118C minus PCV20\] for each serotype at 30 days postdose 4 with V118C and PCV20 will be reported.

    Time frame: Up to approximately 30 days postdose 4

  10. Stage 2: GMCs of Serotype-Specific IgG at 30 Days Postdose 3

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. GMCs of serotype-specific IgG at 30 days postdose 3 with V118C and PCV20 will be reported.

    Time frame: Up to approximately 30 days postdose 3

  11. Stage 2: GMCs of Serotype-Specific IgG at 30 Days Predose 4

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. Serotype-specific IgG GMCs at 30 days predose 4 with V118C and PCV20 will be reported.

    Time frame: Up to approximately 6 months post dose 3

  12. Stage 2: GMCs of Serotype-Specific IgG at 30 Days Postdose 4

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. Serotype-specific IgG GMCs at 30 days postdose 4 with V118C and PCV20 will be reported.

    Time frame: Up to approximately 30 days postdose 4

  13. Stage 2: Ratio of Serotype-Specific IgG GMCs of V118C to PCV20 [V118C/PCV20] at 30 Days Postdose 3

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. Ratio of serotype-specific IgG GMCs of V118C to PCV20 \[V118C/PCV20\] at 30 days postdose 3 will be reported.

    Time frame: Up to approximately 30 days postdose 3

  14. Stage 2: Ratio of Serotype-Specific IgG GMCs of V118C to PCV20 [V118C/PCV20] at 30 Days Postdose 4

    The GMCs for serotype-specific IgG antibodies will be determined using pneumococcal electrochemiluminescence (Pn ECL) assay. Ratio of serotype-specific IgG GMCs of V118C to PCV20 \[V118C/PCV20\] at 30 days postdose 4 will be reported.

    Time frame: Up to approximately 30 days postdose 4

07

Study locations

15 of 15 sites recruiting
  • Madera Family Medical Group ( Site 1004)
    Madera, California 93637, United States
    Recruiting
    • Study Coordinator · Contact559-673-3000
  • Acevedo Clinical Research Associates ( Site 1029)
    Miami, Florida 33142, United States
    Recruiting
    • Study Coordinator · Contact305-649-8871
  • University of South Florida-Department of Pediatrics ( Site 1002)
    Tampa, Florida 33606, United States
    Recruiting
    • Study Coordinator · Contact813-821-8039
  • Cotton O'Neil Research Center ( Site 1039)
    Topeka, Kansas 66604, United States
    Recruiting
    • Study Coordinator · Contact785-354-6000
  • University of Louisville, Norton Children's Research Institute ( Site 1005)
    Louisville, Kentucky 40202, United States
    Recruiting
    • Study Coordinator · Contact502-629-5820
  • The Pediatric Center ( Site 1025)
    Columbia, Maryland 21045, United States
    Recruiting
    • Study Coordinator · Contact443-721-7224
  • Saint Louis University Center for Vaccine Development ( Site 1031)
    St Louis, Missouri 63104, United States
    Recruiting
    • Study Coordinator · Contact314-977-6333
  • Child Health Care Associates ( Site 1035)
    East Syracuse, New York 13057, United States
    Recruiting
    • Study Coordinator · Contact315-652-8800
  • Carolina Family Care ( Site 1021)
    Charleston, South Carolina 29414, United States
    Recruiting
    • Study Coordinator · Contact843-870-2225
  • Tribe Clinical Research, LLC-Pediatrics ( Site 1008)
    Greenville, South Carolina 29607, United States
    Recruiting
    • Study Coordinator · Contact864-334-0141
  • Tribe Clinical Research - Spartanburg ( Site 1001)
    Spartanburg, South Carolina 29301, United States
    Recruiting
    • Study Coordinator · Contact864-334-0141
  • Epic Medical Research - Carrollton ( Site 1038)
    Carrollton, Texas 75006, United States
    Recruiting
    • Study Coordinator · Contact972-777-6956
  • Epic Medical Research- Garland ( Site 1017)
    Garland, Texas 75043, United States
    Recruiting
    • Study Coordinator · Contact972-777-6956
  • University of Texas Medical Branch ( Site 1020)
    League City, Texas 77573, United States
    Recruiting
    • Study Coordinator · Contact832-340-2313
  • Pediatric Research of Charlottesville, LLC ( Site 1012)
    Charlottesville, Virginia 22902, United States
    Recruiting
    • Study Coordinator · Contact434-872-9384
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.

Of 27 phase 1 interventional studies under Pneumococcal Infections, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's planned 33 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2025
First posted
Dec 23, 2025
StartActual
Jan 13, 2026
Primary completionEst.
Oct 24, 2028
CompletionEst.
May 25, 2029
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Carolina Family Care ( Site 1021) · Charleston, United States
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    1 site added
    Show site
    • Carolina Family Care ( Site 1021) · Charleston, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07300267
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Jan 13, 2026
Primary completion
Oct 24, 2028 (estimated)
Completion
May 25, 2029 (estimated)
Last update
Oct 2, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion